Literature DB >> 29377122

Effect of l-caldesmon on osteoclastogenesis in RANKL-induced RAW264.7 cells.

Ying-Ming Liou1,2, Chu-Lung Chan1, Renjian Huang3, Chih-Lueh A Wang3.   

Abstract

Non-muscle caldesmon (l-CaD) is involved in the regulation of actin cytoskeletal remodeling in the podosome formation, but its function in osteoclastogenesis remains to be determined. In this study, RANKL-induced differentiation of RAW264.7 murine macrophages to osteoclast-like cells (OCs) was used as a model to determine the physiological role of l-CaD and its phosphorylation in osteoclastogenesis. Upon RANKL treatment, RAW264.7 cells undergo cell-cell fusion into multinucleate, and TRAP-positive large OCs with a concomitant increase of l-CaD expression. Using gain- and loss-of-function in OC precursor cells followed by RANKL induction, we showed that the expression of l-CaD in response to RANKL activation is an important event for osteoclastogenesis, and bone resorption. To determine the effect of l-CaD phosphorylation in osteoclastogenesis, three decoy peptides of l-CaD were used with, respectively, Ser-to-Ala mutations at the Erk- and Pak1-mediated phosphorylation sites, and Ser-to-Asp mutation at the Erk-mediated phosphorylation sites. Both the former two peptides competed with the C-terminal segment of l-CaD for F-actin binding and accelerated formation of podosome-like structures in RANKL-induced OCs, while the third peptide did not significantly affect the F-actin binding of l-CaD, and decreased the formation of podosome-like structures in OCs. With the experiments using dephosphorylated and phosphorylated l-CaD mutants, we further showed that dephosphorylated l-CaD mutant facilitated RANKL-induced TRAP activity with an increased cell fusion index, whereas phosphorylated l-CaD decreased the TRAP activity and cell fusion. Our findings suggested that both the level of l-CaD expression and the extent of l-CaD phosphorylation play a role in RANKL-induced osteoclast differentiation.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  RANKL; TRAP activity; non-muscle caldesmon (l-CaD); osteoclastogenesis; phosphomimetic peptides; podosome

Mesh:

Substances:

Year:  2018        PMID: 29377122      PMCID: PMC5993584          DOI: 10.1002/jcp.26452

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  41 in total

Review 1.  Therapeutic approaches to bone diseases.

Authors:  G A Rodan; T J Martin
Journal:  Science       Date:  2000-09-01       Impact factor: 47.728

2.  Molecular transporters for peptides: delivery of a cardioprotective epsilonPKC agonist peptide into cells and intact ischemic heart using a transport system, R(7).

Authors:  L Chen; L R Wright; C H Chen; S F Oliver; P A Wender; D Mochly-Rosen
Journal:  Chem Biol       Date:  2001-12

3.  A caldesmon peptide activates smooth muscle via a mechanism similar to ERK-mediated phosphorylation.

Authors:  Renjian Huang; C-L Albert Wang
Journal:  FEBS Lett       Date:  2005-12-06       Impact factor: 4.124

4.  The Rac1 exchange factor Dock5 is essential for bone resorption by osteoclasts.

Authors:  Virginie Vives; Mélanie Laurin; Gaelle Cres; Pauline Larrousse; Zakia Morichaud; Danièle Noel; Jean-François Côté; Anne Blangy
Journal:  J Bone Miner Res       Date:  2011-05       Impact factor: 6.741

5.  Phosphorylated l-caldesmon is involved in disassembly of actin stress fibers and postmitotic spreading.

Authors:  Jolanta Kordowska; Tracy Hetrick; Leonard P Adam; C-L Albert Wang
Journal:  Exp Cell Res       Date:  2005-11-11       Impact factor: 3.905

6.  Cloning of cDNAs encoding human caldesmons.

Authors:  M B Humphrey; H Herrera-Sosa; G Gonzalez; R Lee; J Bryan
Journal:  Gene       Date:  1992-03-15       Impact factor: 3.688

Review 7.  Phosphorylation of caldesmon during smooth muscle contraction and cell migration or proliferation.

Authors:  Jolanta Kordowska; Renjian Huang; Chih-Lueh Albert Wang
Journal:  J Biomed Sci       Date:  2006-03       Impact factor: 8.410

Review 8.  RANKL-RANK signaling in osteoclastogenesis and bone disease.

Authors:  Teiji Wada; Tomoki Nakashima; Nishina Hiroshi; Josef M Penninger
Journal:  Trends Mol Med       Date:  2005-12-13       Impact factor: 11.951

9.  Morphological and biochemical analyses of contractile proteins (actin, myosin, caldesmon and tropomyosin) in normal and transformed cells.

Authors:  J Tanaka; T Watanabe; N Nakamura; K Sobue
Journal:  J Cell Sci       Date:  1993-02       Impact factor: 5.285

Review 10.  Regulation of osteoclasts by membrane-derived lipid mediators.

Authors:  Tsukasa Oikawa; Yukiko Kuroda; Koichi Matsuo
Journal:  Cell Mol Life Sci       Date:  2013-01-08       Impact factor: 9.261

View more
  2 in total

1.  Zoledronic acid inhibits osteoclast differentiation and function through the regulation of NF-κB and JNK signalling pathways.

Authors:  Xiao-Lin Huang; Lie-Yu Huang; Yu-Ting Cheng; Fang Li; Qian Zhou; Chao Wu; Qian-Hui Shi; Zhi-Zhong Guan; Jian Liao; Wei Hong
Journal:  Int J Mol Med       Date:  2019-05-23       Impact factor: 4.101

2.  Effects of urolithin A on osteoclast differentiation induced by receptor activator of nuclear factor-κB ligand via bone morphogenic protein 2.

Authors:  Zhe Wang; Guobin Qi; Zhuokai Li; Xu Cui; Shengyang Guo; Yueqi Zhang; Pan Cai; Xiuhui Wang
Journal:  Bioengineered       Date:  2022-03       Impact factor: 3.269

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.